Back to School: How biopharma can reboot drug development. Access exclusive analysis here

HealthLinx, Proaegis, Monash University gastrointestinal, pulmonary news

Diagnostic company HTX will spin out its CR014 drug development assets into Proaegis.

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE